Fresh analysis indicates that people who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Published data in a leading health publication demonstrates that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing these medications should be informed of the danger of rapid rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment mass within about a year and a half.
Analyzing Therapies
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the effects of the injectable medications with conventional dieting.
The team note that individuals who lose weight through diet and exercise typically see a more gradual creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts suggest the mode of action of the injections is key to understanding the amplified regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means appetite is uncontrolled, making overeating much more probable."
A Lifelong Disease?
The NHS advise the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians say that, given the high risk of relapse, the therapy might need to be life-long.
This opinion is reinforced by drug manufacturers, who note that the results "emphasize the long-term character of excess weight," similar to managing conditions like hypertension.
User Accounts
Users who have come off the medication describe a sudden return of hunger.
"I experienced something flipping and you become ravenous," said one woman.
This challenge is compounded if users have not developed lasting lifestyle or habit modifications during therapy.
Growing Interest
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is higher among females compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a magic fix and long-term success likely depends on ongoing lifestyle management.
